By Kamal Choudhury and Blake Brittain March 3 (Reuters) - Moderna has agreed to pay Genevant Sciences, a subsidiary of ...

Two vaccine candidates using similar technology are winning the COVID-19 vaccine race in the U.S., and in the process validating the mRNA platform — which is yet untested on the market — as well as ...

The Food and Drug Administration authorized Novavax's single-strain vaccine, which targets omicron subvariant XBB.1.5, for emergency use in people ages 12 and up. The Centers for Disease Control and ...

About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. | Moderna will pay $950 ...

Moderna will pay US$950-million upfront in July, 2026, with an additional US$1.3-billion contingent on the outcome of a separate legal appeal, while not owing royalties for the technology in its ...

This ends a drawn out legal battle brought by Genevant and Arbutus against Moderna under a week before the jury trial was set to begin.

Moderna has filed a lawsuit against Pfizer and its German partner BioNTech for allegedly copying their COVID-19 vaccine. On Friday, Moderna issued a news release accusing Pfizer of infringing several ...

WASHINGTON — Pfizer and Moderna say the Food and Drug Administration have opened up COVID-19 booster shots to all adults, letting them choose another dose of either vaccine. The move expands the ...

A recent study suggests people may have protection from the coronavirus for years if they received the Pfizer-BioNTech or Moderna vaccine. The study was published in the journal Nature. “Overall, our ...

Now that Pfizer’s COVID-19 vaccine has gotten full FDA approval, how close is Moderna’s vaccine to the same sign-off? Here's what we know so far. The Food and Drug Administration on Monday granted ...